EMEA-001517-PIP02-14-M03

Key facts

Invented name
Zynquista
Active substance
Sotagliflozin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0226/2021
PIP number
EMEA-001517-PIP02-14-M03
Pharmaceutical form(s)
  • Granules
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of type I diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Guidehouse Germany GmbH

E-mail: KKasslerTaub@lexpharma.com
Tel: +1 9089638536

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating